文献速递骨质疏松与钙磷/甲状旁腺

日本血液透析患者较欧洲患者骨转换更低且骨骼PTH反应性更低

Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients on Hemodialysis.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究为两项前瞻性队列数据的病例对照事后分析,将374例比利时与日本接受慢性间歇性血液透析的患者按年龄、性别、糖尿病和透析时长1:1匹配。日本患者iPTH、BALP和TRAP5b均低于比利时患者,且在任何PTH水平下骨转换标志物均更低,提示骨骼PTH反应性更低。作者认为现行地区间PTH治疗目标差异的依据仍不明确,值得进一步关注。

要点

  • 日本血液透析患者iPTH、BALP、TRAP5b均低于比利时患者。
  • 按PTH水平分层或匹配后,日本患者骨转换标志物仍显著低于比利时患者。
  • 男性、肥胖和高磷血症是骨转换标志物与PTH比值的主要决定因素。

核心结论

  • 日本血液透析患者的骨转换低于欧洲患者,即使在相似PTH水平下亦然,提示日本患者骨骼PTH反应性更低。
  • 作者认为现行地区间PTH治疗目标差异的依据仍不明确,值得进一步关注。

研究设计与样本

  • 研究为两项前瞻性队列研究数据的病例对照事后分析。
  • 纳入接受慢性间歇性血液透析治疗的患者,比利时与日本患者共374例,按年龄(59 ± 12岁)、性别(66%为男性)、糖尿病(34%)和透析时长(39个月[22-63个月])1:1匹配。
  • PTH、骨特异性碱性磷酸酶(BALP)和抗酒石酸酸性磷酸酶5b同工酶(TRAP5b)在比利时列日集中检测。

主要发现

  • 日本患者iPTH为207 pg/mL,比利时患者为268 pg/mL(P < .001)。
  • 日本患者BALP为15.3 μg/L,比利时患者为24.5 μg/L(P < .001)。
  • 日本患者TRAP5b为3.35 U/L,比利时患者为5.79 U/L(P < .001)。
  • 线性回归分析显示,在任何给定PTH水平下,日本患者较比利时患者骨转换标志物水平更低,提示骨骼PTH反应性更低。
  • 按PTH水平分层或匹配后,日本患者骨转换标志物仍显著低于比利时患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Parathyroid hormone (PTH) treatment targets for patients receiving hemodialysis (HD) are lower in Japan than in Europe. Whether this translates to lower bone turnover is unknown and could depend on skeletal PTH responsiveness. OBJECTIVE: This study investigates whether skeletal PTH responsiveness is better preserved in Japanese vs European patients receiving HD. METHODS: This is a post hoc analysis of data from 2 prospective cohort studies, using a case-control design. Patients receiving chronic intermittent HD therapy were eligible for inclusion. Participating Belgian and Japanese patients (n = 374) were matched 1:1 by age (59 ± 12 years), sex (66% male), diabetes (34%), and dialysis duration (39 months [22-63 months]). PTH, bone-specific alkaline phosphatase (BALP), and tartrate-resistant acid phosphatase isoform 5b (TRAP5b) were measured centrally in Liège, Belgium. RESULTS: Japanese patients had lower levels of iPTH (207 vs 268 pg/mL; P < .001), BALP (15.3 vs 24.5 μg/L; P < .001), and TRAP5b (3.35 vs 5.79 U/L; P < .001). Linear regression analyses revealed lower levels of bone turnover markers for any given level of PTH in Japanese vs Belgian patients, indicating lower skeletal PTH responsiveness. Consistently, bone turnover markers were significantly lower in Japanese vs Belgian patients when stratifying or matching according to PTH levels. Male sex, obesity, and hyperphosphatemia were the main determinants of the bone turnover marker/PTH ratios. CONCLUSION: Japanese patients receiving HD have lower bone turnover than their European counterparts, even at similar PTH levels. The rationale for the current regional differences in PTH treatment targets remains obscure and deserves further attention.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Evenepoel P, Jørgensen HS, Komaba H, et al. Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients on Hemodialysis. J Clin Endocrinol Metab. 2022. PMID: 36068939. doi:10.1210/clinem/dgac522

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。